Brokerages expect Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) to report $57.90 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Osmotica Pharmaceuticals’ earnings, with estimates ranging from $51.90 million to $63.90 million. The company is scheduled to issue its next quarterly earnings report on Thursday, August 8th.

On average, analysts expect that Osmotica Pharmaceuticals will report full-year sales of $228.98 million for the current fiscal year, with estimates ranging from $209.85 million to $248.10 million. For the next year, analysts expect that the firm will post sales of $218.12 million, with estimates ranging from $185.23 million to $251.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.08). The firm had revenue of $57.13 million during the quarter, compared to analyst estimates of $53.58 million.

Several research analysts have issued reports on OSMT shares. Barclays started coverage on Osmotica Pharmaceuticals in a research report on Tuesday. They issued an “overweight” rating and a $11.00 price objective for the company. Wells Fargo & Co set a $14.00 price objective on Osmotica Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 28th. Finally, Zacks Investment Research cut Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 25th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $14.00.

Shares of Osmotica Pharmaceuticals stock traded up $0.05 during trading hours on Friday, hitting $3.15. 84,805 shares of the company were exchanged, compared to its average volume of 152,293. Osmotica Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $9.90. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.70 and a quick ratio of 1.41. The stock has a market capitalization of $159.71 million and a PE ratio of -6.18.

A number of institutional investors have recently bought and sold shares of OSMT. JW Asset Management LLC acquired a new stake in Osmotica Pharmaceuticals in the fourth quarter valued at $1,744,000. BlackRock Inc. acquired a new stake in Osmotica Pharmaceuticals in the fourth quarter valued at $3,682,000. Northern Trust Corp acquired a new stake in Osmotica Pharmaceuticals in the fourth quarter valued at $615,000. Geode Capital Management LLC acquired a new stake in Osmotica Pharmaceuticals in the fourth quarter valued at $668,000. Finally, American International Group Inc. acquired a new stake in Osmotica Pharmaceuticals in the fourth quarter valued at $50,000. 11.64% of the stock is currently owned by institutional investors.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Recommended Story: Bear Market

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.